Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Breast Cancer 11/25/2008 - (DGNews)
    Mammogram Most Effective 12 Months After Radiation Treatment - (DGNews)
    Mammograms May Detect Some Cancers That Would Have Otherwise Regressed - (DGNews)
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Mucinous Breast Carcinoma Presenting as Paget's Disease of the Nipple in a Man: A Case Report
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Taxotere/Cyclophosphamide Offers Greater Disease-Free Survival for Early-Stage Breast Cancer Patients: Presented at SABCS

      By Ed Susman

      SAN ANTONIO, TX -- December 13, 2005 -- The combination of docetaxel (Taxotere) and cyclophosphamide should replace doxorubicin (Adriamycin)/cyclophosphamide as the regimen of choice for women with early-stage breast cancer, researchers said here at the 28th Annual San Antonio Breast Cancer Symposium (SABCS).

      "At a median follow-up of 66 months, Taxotere/cyclophosphamide compared to Adriamycin/cyclophosphamide was associated with superior disease-free survival -- a 33% decreased risk," said Stephen Jones, MD, medical director, US Oncology Research, Houston, Texas. The difference in disease-free survival reached statistical significance at the P = .015 level.

      "We also saw a strong trend toward overall survival," Dr. Jones said on December 11th in the final general session. "There was a 24% reduction in the risk of death, which did not reach statistical significance [P = .13]. However, we think that the difference in disease-free survival will eventually translate to a significant overall survival benefit."

      Dr. Jones noted that for more than a generation the combination of Adriamycin and cyclophosphamide had been the standard treatment for women with early-stage breast cancer, but recent studies have indicated that taxanes might offer a better survival benefit for these patients.

      The researchers in 1997 began enrolling 1,016 women and offered 506 of them adjuvant chemotherapy with four cycles of the Taxotere-based therapy consisting of 75-mg/m2 Taxotere and 600-mg/m2 cyclophosphamide every 21 days and offered 510 patients four cycles of the Adriamycin-based chemotherapy with 60-mg/m2 Adriamycin and 600-mg/m2 cyclophosphamide every 21 days.

      All the patients underwent radiation therapy after finishing chemotherapy. After radiation, patients were given tamoxifen if they were found to have hormone-responsive cancer.

      One problem with the Adriamycin combination -- cardiac toxicity -- is not a concern with Taxotere, Dr. Jones said. In his study, he reported, there was no cardiac toxicity in either arm.


      In the trial, breast cancer recurred in 59 patients on the Taxotere regimen (12%); 80 patients on Adriamycin experienced a recurrence (16%).

      "Taxotere/cyclophosphamide (TC) should now be considered as a standard nonanthracycline adjuvant regimen for operable breast cancer," Dr. Jones said.


      [Presentation title: Final analysis: TC (Docetaxel/Cyclophosphamide, 4 Cycles) has a Superior Disease-Free Survival Compared to Standard AC (Doxorubicin/Cyclophosphamide) in 1016 Women With Early Stage Breast Cancer. Abstract 40]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send